Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

AI Industry Working Group

Private

Posts


  • Guidance on which HCP Materials Require PAAB Review
    Jennifer CarrollJ Jennifer Carroll

    Hey @mimi77

    Yes. It would be considered discussion of drug therapy or content relating to drug therapy.

    PAAB Code

  • Unbranded HCP website linking to a PAAB exempt tool
    Jennifer CarrollJ Jennifer Carroll

    Hello @mimi77

    During the review, you’d want to make the reviewer aware of the intended link. They will advise if it can be linked based on the content in the PAAB-exempt piece and the unbranded disease-state piece undergoing review.

    Electronic Media

  • Abstracts and HCP websites
    Jennifer CarrollJ Jennifer Carroll

    Hey @ALee

    Let’s ensure we’re talking about the same thing when we say “abstract”. When we refer to “abstracts” in the response above, we’re speaking to acceptable abstracts (the published abstract from a published peer-reviewed study that meets the standards of the Code).

    This is in contrast to ‘abstracts’ per Code section 3.1.2ii:
    “Please note that abstracts presented at conferences and/or in journal supplements (such as study design and results analyses) that have not been subject to independent review are generally regarded as not having sufficient evidence to support claims and may not be used as reference in APS.”

    The review would require PAAB to see the full published peer-reviewed study and the abstract to ensure the study is acceptable and subsequently, the link to the abstract is acceptable.

    PAAB Q&A

  • Citing patient preference in a patient profile
    Jennifer CarrollJ Jennifer Carroll

    Hello @adelaidebaker

    As a general principle, the clinical decision to prescribe or switch should be made based on clinical considerations. Patient preference can be a part of a patient profile but should not be positioned as the reason to prescribe or switch. Patient preference can be presented as a consideration, without drawing conclusions about clinical actions.
    With respect to the specific case presented in the question, the copy in the guidelines and the APS would have to be assessed at the time of submission. We’d caution that “broadly defined” may be problematic and that drawing inference around patient choice such as “difficulty remembering to take pills and therefore might prefer injections” would require statistically significant evidence from a published high quality source.

    General Discussion

  • PAAB Forum Quarterly Review and eFiles Tag and CEI Report - Q2 - 2025
    Jennifer CarrollJ Jennifer Carroll

    Good Afternoon @Manufacturer and @Agency

    It's crazy to say but we're now just past halfway through 2025!

    The PAAB Quarterly Tag and CEI Reports have been updated to contain data for Q2. See the Tag report here and the CEI report here.

    The Forum Quarterly Review for Q2 has also been posted here.

    If there's more you'd like to know in Q3, let us know in the comments below. Have a wonderful rest of the summer.

    Thank you
    PAAB

    Blogs

  • Product is "in stock" claim
    Jennifer CarrollJ Jennifer Carroll

    Hi @support

    A strictly informational statement about stock such as “Product X 5mg dose now back in stock” could be considered exempt.

    The inclusion of the indication statement renders it no longer exempt.
    The inclusion of a product photo MAY render it no longer exempt. This piece should likely be submitted for an exempt opinion to assess if the product photo can be used while meeting exempt criteria.

    General Discussion

  • eFiles - Scheduled Down Time - July 29th, 5pm-12am
    Jennifer CarrollJ Jennifer Carroll

    Good morning, @Manufacturer @Agency

    PAAB will be performing an upgrade to the eFiles system tonight, July 29th. We will be shutting the eFiles system down from 5pm-midnight to perform the upgrade. Please note that users will not have access to eFiles during this time.

    We’re sorry for any inconvenience that this causes.

    Thank you
    PAAB

    Announcements

  • Product is "in stock" claim
    Jennifer CarrollJ Jennifer Carroll

    Hey @support

    A simple availability message such as “Product X is now back in stock” would be considered exempt. To remain exempt it should be limited to an informational message (not linked to therapeutic or promotional messages) about stock. (s1.5D)

    General Discussion

  • Dosing information and off-label competitors in retrospective cohort studies
    Jennifer CarrollJ Jennifer Carroll

    Hey @dmauri
    Great question. As long as the study publication does not contain information suggesting dosing practices inconsistent with Canadian labelling, the manufacturer’s Medical/Regulatory Affairs department can confirm that the dosing in the jurisdiction where the study was conducted is the same as it is in Canada.

    When it comes to “SoC”, per 1.7 of the Guidance on Real-World Evidence/Data, remember that pooled comparisons are not acceptable which would render the second half of the question moot. However, if you are referring to SoC in a single-arm study (per Advisory: RWE Single-Arm Studies of Previously Treated Patients), we would look to ensure that the overwhelming majority of patients were on a product available in Canada/indicated in the same population in Canada. Regarding "SoC", please note the guidance's remarks on representing the marketplace versus exclusions by design. An opinion can be a great mechanism to get specific guidance on an individual study as it allows for assessment of the study design, therapeutic area, and indicated product(s).

    Real World Evidence (RWE)

  • Implications of updated safety information in Product Monograph
    Jennifer CarrollJ Jennifer Carroll

    Hey @JDilly11

    Hard to provide comments without seeing the updated TMA copy. This question is likely better submitted as an opinion so that we can look at the update and the nature of the claims being made in current or proposed future pieces. As a general guiding principle, the assessment is made by looking at the update in combination with the APS copy to ensure it reflects the same context as the TMA. If there is something that would trigger the inclusion, then it will likely have to be added. Whether both data presentations are required will also depend on the APS copy and the finalized TMA copy.

    Claims & Support/References for Claims

Member List

Jennifer CarrollJ Jennifer Carroll
Patrick MassadP Patrick Massad
S samra.rehman
C ColetteMH
M micheleparent
M MariaD
F Farinam
B bryanroman
B BMarinac
J Jon
J jliang
J jgchiriboga
C camillekiffer
M melissaferlaino
C costeap
D Daniellea
T Tommy-Lam
NatBourreN NatBourre
S simonsmith
M mef
  • Login

  • Don't have an account? Register

  • Login or register to search.
  • First post
    Last post
0
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups